Zentalis Pharmaceuticals (ZNTL) News Today $1.87 -0.11 (-5.56%) Closing price 04:00 PM EasternExtended Trading$1.84 -0.03 (-1.34%) As of 05:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025March 25 at 4:40 PM | globenewswire.comZentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Monday.March 18, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Zentalis Pharmaceuticals (NASDAQ:ZNTL)March 18, 2025 | americanbankingnews.comZentalis presents updated clinical data on azenosertib as SGO 2025March 16, 2025 | markets.businessinsider.comZentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s CancerMarch 15, 2025 | finance.yahoo.comZentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's CancerMarch 15, 2025 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from BrokeragesShares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have received a consensus rating of "Hold" from the nine analysts that are currently covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold rating and four have given a buy rating to the companMarch 9, 2025 | marketbeat.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 3, 2025 | globenewswire.comZentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s CancerMarch 3, 2025 | markets.businessinsider.comZentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's CancerMarch 3, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLFebruary 25, 2025 | prnewswire.comZentalis Pharmaceuticals to Participate in Upcoming Investor ConferencesFebruary 24, 2025 | globenewswire.comZentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying RecentlyFebruary 21, 2025 | msn.com10 Cheapest Stocks Insiders Are Buying RecentlyFebruary 20, 2025 | insidermonkey.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLFebruary 18, 2025 | prnewswire.comZentalis Pharmaceuticals (ZNTL) Expected to Announce Quarterly Earnings on TuesdayZentalis Pharmaceuticals (NASDAQ:ZNTL) will be releasing earnings before the market opens on Tuesday, February 25.February 18, 2025 | marketbeat.comZentalis Pharmaceuticals' chief medical officer acquires $45,656 in stockFebruary 13, 2025 | msn.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Ingmar Bruns Purchases 20,000 SharesFebruary 13, 2025 | insidertrades.comInsider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Insider Buys 20,000 Shares of StockZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) insider Ingmar Bruns bought 20,000 shares of the stock in a transaction dated Thursday, February 6th. The stock was bought at an average cost of $2.28 per share, with a total value of $45,600.00. Following the purchase, the insider now owns 36,629 shares in the company, valued at $83,514.12. The trade was a 120.27 % increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.February 12, 2025 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by AnalystsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received a consensus rating of "Hold" from the nine research firms that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and four have issued a buy rating on the compaFebruary 12, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLFebruary 11, 2025 | prnewswire.comQ3 Earnings Forecast for ZNTL Issued By Leerink PartnrsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens expects that the cFebruary 10, 2025 | marketbeat.comQ1 Earnings Forecast for ZNTL Issued By Leerink PartnrsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will postFebruary 7, 2025 | marketbeat.comZentalis Pharmaceuticals chief legal officer sells $22,643 in stockFebruary 5, 2025 | msn.comZentalis pharmaceuticals officer sells $24,590 in stockFebruary 5, 2025 | msn.comInsider Buying: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Buys 60,000 Shares of StockFebruary 5, 2025 | insidertrades.comZentalis pharmaceuticals director Jan Skvarka buys $103,446 in stockFebruary 4, 2025 | msn.comZentalis pharmaceuticals director Luke Walker buys $24,966 in stockFebruary 4, 2025 | msn.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Director Jan Skvarka Purchases 60,000 SharesZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) Director Jan Skvarka bought 60,000 shares of the stock in a transaction dated Friday, January 31st. The stock was bought at an average price of $1.72 per share, with a total value of $103,200.00. Following the acquisition, the director now owns 149,551 shares in the company, valued at approximately $257,227.72. This represents a 67.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.February 4, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTLFebruary 4, 2025 | prnewswire.comZentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)February 3, 2025 | globenewswire.comHC Wainwright Issues Optimistic Forecast for ZNTL EarningsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a report released on Wednesday, January 29th. HC Wainwright analyst A. Fein now expects that the companFebruary 3, 2025 | marketbeat.comLeerink Partnrs Issues Positive Estimate for ZNTL EarningsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Stock analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst A. Berens now anticFebruary 3, 2025 | marketbeat.comEquities Analysts Set Expectations for ZNTL FY2024 EarningsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Analysts at Wedbush lifted their FY2024 earnings estimates for shares of Zentalis Pharmaceuticals in a report released on Wednesday, January 29th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share oFebruary 3, 2025 | marketbeat.comFY2029 Earnings Forecast for ZNTL Issued By HC WainwrightZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research report issued on Wednesday, January 29th. HC Wainwright analyst A. Fein anticipates that the company will post earnings of (January 31, 2025 | marketbeat.comEquities Analysts Offer Predictions for ZNTL FY2029 EarningsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at Wedbush issued their FY2029 earnings per share estimates for shares of Zentalis Pharmaceuticals in a report issued on Wednesday, January 29th. Wedbush analyst R. Driscoll forecasts that the company will post earniJanuary 31, 2025 | marketbeat.comZentalis stock price target cut to $10 by H.C. WainwrightJanuary 31, 2025 | msn.comHold Rating Maintained on Zentalis Pharmaceuticals Amid Uncertainties and Regulatory ScrutinyJanuary 31, 2025 | markets.businessinsider.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $6.00 Price Target at Wells Fargo & CompanyWells Fargo & Company reduced their target price on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an "equal weight" rating on the stock in a report on Thursday.January 30, 2025 | marketbeat.comZentalis Pharmaceuticals Faces Delays and Challenges in Azeno Development, Justifying Hold RatingJanuary 30, 2025 | markets.businessinsider.comZentalis Pharmaceuticals: Hold Rating Amid Promising Data and Cautious OutlookJanuary 30, 2025 | markets.businessinsider.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest UpdateZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 4,540,000 shares, a decline of 17.5% from the December 31st total of 5,500,000 shares. Based on an average daily trading volume, of 1,310,000 shares, the days-to-cover ratio is presently 3.5 days.January 30, 2025 | marketbeat.comStrategic Focus on Azenosertib Positions Zentalis Pharmaceuticals for Success in Ovarian Cancer TreatmentJanuary 29, 2025 | markets.businessinsider.comJefferies cuts Zentalis stock target to $2.50; maintains holdJanuary 29, 2025 | msn.comZentalis Pharmaceuticals Stock Plunges After 40% Workforce Cut AnnouncementJanuary 29, 2025 | markets.businessinsider.comOppenheimer cuts Zentalis stock target to $10, maintains ratingJanuary 29, 2025 | msn.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Given New $10.00 Price Target at HC WainwrightHC Wainwright decreased their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday.January 29, 2025 | marketbeat.comZentalis Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) was the target of some unusual options trading activity on Wednesday. Investors acquired 2,113 call options on the company. This represents an increase of 571% compared to the typical daily volume of 315 call options.January 29, 2025 | marketbeat.comZentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian CancerJanuary 29, 2025 | globenewswire.comZentalis to reduce workforce by 40% in business restructuringJanuary 29, 2025 | markets.businessinsider.com Remove Ads Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address ZNTL Media Mentions By Week ZNTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZNTL News Sentiment▼0.300.62▲Average Medical News Sentiment ZNTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZNTL Articles This Week▼03▲ZNTL Articles Average Week Remove Ads Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies URGN News Today SANA News Today TYRA News Today PGEN News Today RLAY News Today OPT News Today ORIC News Today MNMD News Today MAZE News Today SION News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZNTL) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZNTL Stock Free ZNTL Stock Alerts